Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-CD19 fully human antibody and immune effector cells targeting CD19

A fully human antibody and immune cell technology, applied in the field of tumor immunotherapy or diagnosis, can solve problems affecting clinical use

Active Publication Date: 2019-04-23
上海科济制药有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the antibody used in some products such as Blinatumomab is mouse anti-CD19 antibody, so it is possible to produce human anti-mouse antibody (HAMA) reaction in the human body, affecting its clinical use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-CD19 fully human antibody and immune effector cells targeting CD19
  • Anti-CD19 fully human antibody and immune effector cells targeting CD19
  • Anti-CD19 fully human antibody and immune effector cells targeting CD19

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Example 1. Preparation of a specific single-chain antibody (scFv) that binds to human CD19

[0111] 1.1 Screening of human CD19-specific binding antibodies based on phage display

[0112] Using phage display technology, human CD19-specific antibodies were screened from a fully human natural antibody library. For this purpose, 400ml of 2×YT / ampicillin culture medium was inoculated with glycerol bacteria (purchased from Shanghai Ruijin Biotechnology Co., Ltd.) displaying a natural library of fully human single-chain antibodies on phage, so that the cell density reached OD600=0.1, at 37 Under the condition of ℃ and 200rpm, shake culture until the cell density reaches OD600=0.5. use 10 12 pfu of M13KO7 helper phage (purchased from Invitrogen) was infected and incubated at 30° C. and 50 rpm for 30 minutes. After adding 50mg / l kanamycin, shake and culture at 37°C and 200rpm for 30 minutes, separate the precipitate by centrifugation (15 minutes, 1600×g, 4°C), resuspend in 4...

Embodiment 2

[0129] Example 2, Expression and Purification of Anti-CD19 Single Chain Antibody

[0130] 2.1 Preparation of human CD19 single chain antibody

[0131] Use the primer pair V5-1F1-F (SEQ ID NO:17) and V5-1F1-R (SEQ ID NO:18) to amplify the scFv-1F1 fragment from the clone pCantab-1F1 obtained in Example 1; use the primer pair V5-1H11-F (SEQ ID NO: 19) and V5-1H11-R (SEQ ID NO: 20) amplified scFv-1H11 fragments from the obtained clone pCantab-1H11, and passed NheI / BamHI (purchased from NEB) double Digestion with T4 DNA ligase in the same double digestion with NheI / BamHI vector plasmid pCMV-V5-Fc (this vector is fused to express the Fc fragment of human IgG1 antibody downstream of the multiple cloning site, hereinafter referred to as V5-Fc, purchased from Shanghai Ruijin Biotechnology Co., Ltd.) was ligated and transformed into the host strain TOP10, and the positive clones were picked and identified by PCR and confirmed by sequencing, and the eukaryotic expression plasmids of V5...

Embodiment 3

[0137] Example 3. Antigen-binding activity analysis of single-chain antibody against human CD19

[0138] The binding activity of the screened antibodies to the antigen human CD19 was determined by concentration gradient ELISA experiments. For this purpose, use 0.1M NaHCO 3 (pH 9.6) Antigen human CD19 was diluted with coating solution, 100ng per well, 50μl / well, overnight at 4°C, and coated with 2% (w / v) BSA and 0.01% (v / v) Tween-20 Block with PBST blocking solution for 2 hours at room temperature. Plates were then rinsed three times with PBST and removed. Subsequently, 100 μl of PBST solution containing a series of concentrations (initial concentration 10 nM, 3-fold serial dilution, until diluted to 1:729) of each antibody protein was added to each well plate, and the determination of each sample was performed using parallel triplicate analysis. . After incubation at 37°C for 2 hours, rinse with PBST three times, then add 100 μl / well of horseradish peroxidase-labeled goat ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an anti-CD19 fully human antibody and immune effector cells targeting CD19. The invention discloses a new fully human antibody specifically recognizing CD19, and the antibody of the invention can be applied to the preparation of targeted anti-tumor drugs and drugs for diagnosing tumors.

Description

technical field [0001] The invention belongs to the field of tumor immunotherapy or diagnosis, and more specifically, the invention relates to an anti-CD19 fully human antibody and immune effector cells targeting CD19. Background technique [0002] B cell malignancies include non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). At present, B cell malignancies mainly include chemotherapy, radiotherapy, bone marrow transplantation and peripheral blood stem cell transplantation. Despite these treatments, most patients still cannot be cured. [0003] CD19 is a glycoprotein with a molecular weight of 95kDa, expressed in B cells at various stages from early development to differentiation into plasma cells. CD19 is only expressed in B lineage cells, not in pluripotent blood stem cells. CD19 is also expressed in most B-cell lymphomas, mantle cell lymphoma, ALL, CLL, hairy cell leukemia and some acute myeloid leukemia. CD19 is n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61K47/68A61P35/00G01N33/574C07K19/00C12N15/62C12N5/10
CPCC07K14/7051C07K2319/03A61K39/0011A61K39/4611A61K39/4631A61K39/464412
Inventor 宋波石志敏王鹏王华茂李宗海
Owner 上海科济制药有限公司